TW200514582A - Transdermal preparation and method for reducing side effect in pergolide therapy - Google Patents

Transdermal preparation and method for reducing side effect in pergolide therapy

Info

Publication number
TW200514582A
TW200514582A TW093132615A TW93132615A TW200514582A TW 200514582 A TW200514582 A TW 200514582A TW 093132615 A TW093132615 A TW 093132615A TW 93132615 A TW93132615 A TW 93132615A TW 200514582 A TW200514582 A TW 200514582A
Authority
TW
Taiwan
Prior art keywords
transdermal preparation
pergolides
side effect
reducing side
pergolide
Prior art date
Application number
TW093132615A
Other languages
English (en)
Inventor
Arata Toshimitsu
Kazunosuke Aida
Takaaki Terahara
Naruhito Higo
Original Assignee
Hisamitsu Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co filed Critical Hisamitsu Pharmaceutical Co
Publication of TW200514582A publication Critical patent/TW200514582A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093132615A 2003-10-31 2004-10-27 Transdermal preparation and method for reducing side effect in pergolide therapy TW200514582A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003373601 2003-10-31

Publications (1)

Publication Number Publication Date
TW200514582A true TW200514582A (en) 2005-05-01

Family

ID=34544147

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093132615A TW200514582A (en) 2003-10-31 2004-10-27 Transdermal preparation and method for reducing side effect in pergolide therapy

Country Status (5)

Country Link
US (2) US20070082037A1 (zh)
EP (1) EP1679075A4 (zh)
JP (1) JPWO2005041967A1 (zh)
TW (1) TW200514582A (zh)
WO (1) WO2005041967A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8041603B2 (en) * 2004-02-05 2011-10-18 Alex Suk System and method for reimbursing merchants for redeemed electronic coupons
JP5097359B2 (ja) 2006-05-09 2012-12-12 久光製薬株式会社 ドネペジル経皮吸収型製剤
NO3175985T3 (zh) 2011-07-01 2018-04-28
US20150045305A1 (en) 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
MX2015013727A (es) * 2013-04-04 2016-02-29 Hyundai Pharm Co Ltd Composicion para preparacion de uso externo con permeabilidad transdermica mejorada.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
US5693335A (en) * 1995-06-07 1997-12-02 Cygnus, Inc. Skin permeation enhancer composition for use with sex steroids
US6623752B1 (en) * 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
DE19821788C1 (de) * 1998-05-15 1999-12-02 Sanol Arznei Schwarz Gmbh Transdermales Therapeutisches System (TTS) Pergolid enthaltend
EP1233763B1 (de) * 1999-11-29 2003-07-30 LTS Lohmann Therapie-Systeme AG Transdermale therapeutische systeme mit verbesserter stabilität und ein verfahren zu ihrer herstellung
JP2003531157A (ja) * 2000-04-26 2003-10-21 ワトソン ファーマシューティカルズ， インコーポレイテッド オキシブチニン治療に関連した有害な経験の最小化
EP1340496A4 (en) * 2000-11-07 2004-04-14 Hisamitsu Pharmaceutical Co PHARMACEUTICAL PREPARATION OF THE PERCUTANEOUS ABSORPTION TYPE
BR0207955A (pt) * 2001-03-07 2004-02-25 Hisamitsu Pharmaceutical Co Agente de emplastro
CA2443128A1 (en) * 2001-03-30 2002-10-10 Debra A. Martin Transdermal delivery of pergolide
JP4404251B2 (ja) * 2001-08-10 2010-01-27 久光製薬株式会社 経皮吸収型製剤
JP4271028B2 (ja) * 2001-08-10 2009-06-03 久光製薬株式会社 経皮吸収型製剤
KR20050037405A (ko) * 2001-10-17 2005-04-21 히사미쯔 제약 주식회사 경피 흡수형 제제
JP4213432B2 (ja) * 2002-08-28 2009-01-21 久光製薬株式会社 貼付剤
JP4792193B2 (ja) * 2002-08-28 2011-10-12 久光製薬株式会社 貼付剤
JP5547065B2 (ja) * 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤

Also Published As

Publication number Publication date
US20070082037A1 (en) 2007-04-12
US20080188509A1 (en) 2008-08-07
JPWO2005041967A1 (ja) 2007-11-29
EP1679075A1 (en) 2006-07-12
WO2005041967A1 (ja) 2005-05-12
EP1679075A4 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
IS2803B (is) Fentanýlsamsetning fyrir gjöf í nef
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
CA2518971A1 (en) Composition for administration of iron for the treatment of restless legs syndrome
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
DE602004018735D1 (de) Argon enthaltendes Arzneimittel zum Inhalieren und dessen Verwendung zur Behandlung von Neurotoxizität
IL173346A0 (en) Treatment of dependence withdrawal
MXPA02009237A (es) Metodos para tratar la disfuncion sexual con apomorfina, a niveles especificos de concentracion en el plasma.
MXPA05007287A (es) Formulacion y metodos para el tratamiento de trombocitemia.
TW200514582A (en) Transdermal preparation and method for reducing side effect in pergolide therapy
HK1049105A1 (zh) 磷酸二酯酶4抑制剂的使用方法
WO2001074365A3 (en) An efficacious dosage regimen of galantamine that reduces side effects
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
MXPA04001805A (es) Nueva forma de dosificacion oral de liberacion prolongada.
WO2007079195A3 (en) Gastric retentive gabapentin dosage forms and methods for using same
WO2004028457A3 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY
AU4258601A (en) Divided dose therapies with vascular damaging activity
UA40736U (en) METHOD FOR TREATMENT OF VERTEBROGENIUOS radiculopathy
WO2006024044A3 (en) Composition and method for altering levels of or sensitivity to adenosine with analogs of dehydroepiandrostone
UA38286U (ru) Способ лечения ревматоидного артрита
UA50328A (uk) Спосіб лікування атоній передшлунків великої рогатої худоби
UA36766A (uk) Спосіб лікування хворих на хронічний алкогольний гепатит
UA4663U (uk) Спосіб лікування гострого сальпінгоофориту
UA42427A (uk) Спосіб корекції целюліту та/або локальних жирових відкладень